New hepatitis C drugs approved by NICE

Following review by NICE, the protease inhibitors boceprevir (Victrelis) and telaprevir (Incivo) have been approved for use on the NHS for the treatment of chronic hepatitis C genotype 1 infection.

Victrelis and Incivo are licensed for the treatment of hepatitis C genotype 1 infection in both treatment-naïve and treatment-experienced adults | SCIENCE PHOTO LIBRARY
Victrelis and Incivo are licensed for the treatment of hepatitis C genotype 1 infection in both treatment-naïve and treatment-experienced adults | SCIENCE PHOTO LIBRARY
The antivirals are licensed for use in adults with compensated liver disease who are treatment-naive or in whom previous treatment with interferon alfa (pegylated or non-pegylated), alone or in combination with ribavirin, has failed.

Boceprevir and telaprevir are orally active and suppress viral replication via inhibition of the HCV NS3 protease. They are both used in combination with peginterferon alfa and ribavirin; telaprevir is given for 12 weeks and boceprevir for up to 44 weeks.

Guidance summaries

NICE guidance on boceprevir

NICE guidance on telaprevir

Further details

View Victrelis drug record

View Incivo drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in